Related Experiment Video
Updated: Feb 17, 2026
A Protocol for Functional Assessment of Whole-Protein Saturation Mutagenesis Libraries Utilizing High-Throughput Sequencing
Published on: July 3, 2016
Temocillin for non-urinary tract infections caused by AmpC-producing Enterobacterales: Is it a feasible option?
Christel Mamona-Kilu1, Bui Hai Hoang2, Eric Farfour3
1Infectious Disease Department, University Hospital R. Poincaré, Garches, APHP, France.
Background:
Infections due to AmpC-producing Enterobacterales represent an increasing therapeutic challenge. Third-generation cephalosporins may select resistant mutants, inducing clinicians to use cefepime or carbapenems and thereby contributing to carbapenem resistance. While temocillin is a narrow-spectrum beta-lactam stable against AmpC enzymes, evidence of its impact in non-urinary tract infections remains limited.
Methods:
We conducted a retrospective study of adult patients treated with temocillin for non-urinary tract infections caused by AmpC-producing Enterobacterales between 2016 and 2021. Clinical, microbiological and therapeutic data were collected. The primary outcome was treatment failure within twenty-eight days.
Results:
Six patients were included, with a median age of sixty-one years; three required intensive care. Infection sites were digestive or respiratory. All patients had achieved clinical cure by day twenty-eight, without recurrence, infection-related mortality, or adverse events.
Conclusion:
Having led to favorable outcomes, temocillin may represent a carbapenem-sparing option when in vitro susceptibility is confirmed. These findings call for further evaluation in larger prospective clinical studies.
Insights
Temocillin shows promise as a carbapenem-sparing antibiotic for AmpC-producing Enterobacterales infections outside the urinary tract. All patients in this study achieved clinical cure, suggesting its potential efficacy.
Area of Science:
- Infectious Diseases
- Antimicrobial Resistance
- Clinical Pharmacology
Background:
- AmpC-producing Enterobacterales infections pose a significant therapeutic challenge.
- Third-generation cephalosporins can promote resistance, leading to increased carbapenem use.
- Temocillin is a beta-lactam effective against AmpC enzymes, but its use in non-urinary infections is understudied.
Purpose of the Study:
- To evaluate the efficacy of temocillin in treating non-urinary tract infections caused by AmpC-producing Enterobacterales.
- To assess temocillin's potential as a carbapenem-sparing agent.
Main Methods:
- Retrospective study of adult patients treated with temocillin for non-urinary tract infections.
- Data collected on clinical, microbiological, and therapeutic parameters.
- Primary outcome: treatment failure within 28 days.
Main Results:
- Six patients with digestive or respiratory infections were included.
- All patients achieved clinical cure by day 28.
- No recurrence, infection-related mortality, or adverse events were observed.
Conclusions:
- Temocillin demonstrated favorable outcomes in this small cohort.
- It may serve as a carbapenem-sparing option for susceptible infections.
- Further prospective studies are warranted to confirm these findings.
Related Concept Videos
01:28Antimicrobial Effectiveness
01:30Development of Antibiotic Resistance
00:57Antibiotic Selection